| 491 |
GAVISCON SUSPENSION |
SODIUM ALGINATE 500 MG, SODIUM BICARBONATE 267 MG, CALCIUM CARBONATE 160 MG |
SUSPENSION |
SACHET |
TREATMENT OF SYMPTOMS OF GASTRO-OESOPHAGEAL REFLUX SUCH AS ACID REGURGITATION, HEARTBURN AND INDIGESTION RELATED TO REFLUX, FOR EXAMPLE, FOLLOWING MEALS, OR DURING PREGNANCY, OR IN PATIENTS WITH SYMPTOMS RELATED TO REFLUX OESOPHAGITIS |
NULL |
DKSH LAOS COMPANY LIMITED |
RECKITT BENCKISER HEALTHCARE(UK)LIMITED |
UNITED KINGDOM |
CERTIFICATE RELEASED |
01 I 5373/23 |
23-Jan-2023 |
22-Jan-2026 |
View |
| 492 |
GLAKAY 15MG |
MENATETRENONE 15MG |
CAPSULE |
BLISTERPACK |
IMPROVEMENT OF BONE MASS DECREASE AND RELIEF OF BACK PAIN IN PATIENTS WITH OSTEOPOROSIS |
NULL |
DKSH LAOS COMPANY LIMITED |
SHIBAKAWA PLANT OF FUJI CAPSULE CO.,LTD |
THAILAND |
CERTIFICATE RELEASED |
01 I 2871/07 |
31-Mar-2023 |
30-Mar-2026 |
View |
| 493 |
GLIFORWAN FORTE 2.5 |
METFORMIN HYDROCHLORIDE USP 500 MG, GLIBENCLAMIDE BP 2.5 MG |
FILM COATED TABLET |
ALU-PVC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULTS, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCLAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
NULL |
DKSH LAOS COMPANY LIMITED |
MASCOT HEALTH SERIES PVT.LTD |
INDIA |
CERTIFICATE RELEASED |
02 I 5693/24 |
26-FEB-2024 |
25-FEB-2027 |
View |
| 494 |
GLIFORWAN FORTE 5 |
METFORMIN HYDROCHLORIDE USP 500 MG, GLIBENCLAMIDE BP 5 MG |
FILM COATED TABLET |
ALU-PVC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULTS, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCLAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
NULL |
DKSH LAOS COMPANY LIMITED |
MASCOT HEALTH SERIES PVT.LTD |
INDIA |
CERTIFICATE RELEASED |
02 I 5694/24 |
26-FEB-2024 |
25-FEB-2027 |
View |
| 495 |
GLUCOPHAGE 500 MG |
METFORMIN HYDROCHLORIDE 500 MG EQ.TO METFORMIN BASE 390 MG |
FILM COATED TABLET |
PVC-ALUMINIUM |
TREATMENT OF TYPE 2 DIABETES IN ADULT, PARTICULARLY IN OVERWEIGHT PATIENTS, WHEN DIETARY MANAGEMENT AND EXCERCISE ALONE DOES NOT RESULT IN ADEQUATE GLYCAEMIC CONTROL |
NULL |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5045/21 |
22-JUN-2024 |
21-JUN-2027 |
View |
| 496 |
GLUCOPHAGE 850 MG |
METFORMIN HYDROCHLORIDE 850 MG EQ.TO METFORMIN BASE 662.90 MG |
FILM COATED TABLET |
PVC-ALUMINIUM |
TREATMENT OF TYPE 2 DIABETES IN ADULT, PARTICULARLY IN OVERWEIGHT PATIENTS, WHEN DIETARY MANAGEMENT AND EXCERCISE ALONE DOES NOT RESULT IN ADEQUATE GLYCAEMIC CONTROL |
NULL |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5046/21 |
22-JUN-2024 |
21-JUN-2027 |
View |
| 497 |
GLUCOVANCE 500 MG/2.5 MG |
METFORMIN HYDROCHLORIDE 500 MG, GLIBENCLAMIDE 2.5 MG |
FILM COATED TABLET |
PVC-PVDC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULT, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
NULL |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5047/21 |
22-JUN-2024 |
21-JUN-2027 |
View |
| 498 |
GLUCOVANCE 500 MG/5MG |
METFORMIN HYDROCHLORIDE 500 MG, GLIBENCLAMIDE 5 MG |
FILM COATED TABLET |
PVC-PVDC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULT, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
NULL |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5048/21 |
22-JUN-2024 |
21-JUN-2027 |
View |
| 499 |
GLUFAST 10 MG |
MITIGLINIDE CALCIUM HYDRATE 10 MG |
TABLET |
BLISTERPACK |
FOR IMPROVEMENT IN POSTPRANDIAL PLASMA GLUCOSE TRANSITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO EXPERIENCE INADEQUATE RESPONSE TO ANY OF THE FOLLOWING TREATMENTS.
(1) DIETARY TREATMENT AND EXERCISE THERAPY ALONE . (2) USE OF Α-GLUCOSIDASE INHIBITORS, IN ADDITION TO DIET AND PHYSICAL EXERCISE.
|
NULL |
DKSH LAOS COMPANY LIMITED |
KISSEI PHARMACEUTICAL CO.,LTD |
THAILAND |
CERTIFICATE RELEASED |
06 I 4500/18 |
25-SEP-2024 |
24-SEP-2029 |
View |
| 500 |
GYNOFLOR |
LACTOBACILLUS ACIDOPHILUS CULTURE LYOPHILISATE 50 MG, (WITH AT LEAST 10E8 50 MG VIABLE CFU),
ESTRIOL 0.03 MG,
|
VAGINAL TABLET |
BLISTERPACK |
RESTORATION OF THE LACTOBACILLUS FLORA AFTER LOCAL AND/OR SYSTEMIC TREATMENT WITH ANTI-INFECTIVE OR CHEMOTHERAPEUTIC AGENTS, ATROPHIC VAGINITIS DUE TO ESTROGEN DEFICIENCY DURING MENOPAUSE AND POST-MENOPAUSE… |
NULL |
DKSH LAOS COMPANY LIMITED |
HAUPT PHARMA AMAREG GMBH |
GERMANY |
CERTIFICATE RELEASED |
02 I 2740/06 |
16-JAN-2025 |
15-JAN-2030 |
View |
